Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028:… EP News Bureau Mar 21, 2024 GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma EP News Bureau Jul 31, 2020 The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf…
